Inhibition of warm ischemic injury to rat liver, pancreas, and heart grafts by controlling the nutritional status of both donor and recipient.
In this study, we tested the effect of donor fasting with or without the use of an essential fatty acids deficiency (EFAD) diet in the recipient using rat heart, pancreas, and liver transplant models. We then compared the survivals, tumor necrosis factor alpha (TNF-alpha) response, and white cell accumulation in rats in order to clarify the mechanisms of the beneficial effect of donor fasting and recipient EFAD. It was found that when the grafts were obtained from fasted donors and then transplanted into fed recipients, the survival rate was significantly higher for all three grafts than for those obtained from fed rats and transplanted into fed rats. The best survival was seen for pancreas grafts obtained from fasted donors and then transplanted into EFAD recipients. TNF-alpha secretion was significantly suppressed in both fasted and EFAD rats, and both the total cell count and neutrophil count were suppressed in EFAD rats. These results clearly indicate that in addition to liver grafts, both heart and pancreas grafts obtained from fasted animals are more tolerant to warm ischemic injury. Furthermore, the combination of donor fasting and recipient EFAD acts synergistically to inhibit the post-transplantation inflammatory reaction (through decreased TNF-alpha secretion and white cell accumulation), thus resulting in an improved survival.
Nishihara
V
V
Second Department of Surgery, School of Medicine, Hiroshima University, Japan.
Sumimoto
R
R
Fukuda
Y
Y
Southard
J H
JH
Asahara
T
T
Dohi
K
K
D000818:Animals; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005215:Fasting; D005228:Fatty Acids, Essential / Q000172:deficiency*; D016027:Heart Transplantation; D016031:Liver Transplantation; D009752:Nutritional Status; D016035:Pancreas Transplantation; D051381:Rats; D015427:Reperfusion Injury / Q000517:prevention & control*; D016042:Transplantation, Heterotopic; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D015054:Zymosan
D005228:Fatty Acids, Essential; D014409:Tumor Necrosis Factor-alpha; D015054:Zymosan